7LPQ
Crystal structure of Cryptococcus neoformans sterylglucosidase 1 with hit 9
7LPQ の概要
| エントリーDOI | 10.2210/pdb7lpq/pdb |
| 分子名称 | Cytoplasmic protein, ~{N}-[(3~{R},5~{S})-5-(hydroxymethyl)-1-methyl-pyrrolidin-3-yl]-2-(3-oxidanylidene-4~{H}-1,4-benzoxazin-6-yl)ethanamide, GLYCEROL, ... (5 entities in total) |
| 機能のキーワード | glucosidase, sterylglucosidase, hydrolase |
| 由来する生物種 | Cryptococcus neoformans var. grubii serotype A (strain H99 / ATCC 208821 / CBS 10515 / FGSC 9487) (Filobasidiella neoformans var. grubii) 詳細 |
| タンパク質・核酸の鎖数 | 4 |
| 化学式量合計 | 358554.39 |
| 構造登録者 | |
| 主引用文献 | Pereira de Sa, N.,Taouil, A.,Kim, J.,Clement, T.,Hoffmann, R.M.,Burke, J.E.,Rizzo, R.C.,Ojima, I.,Del Poeta, M.,Airola, M.V. Structure and inhibition of Cryptococcus neoformans sterylglucosidase to develop antifungal agents. Nat Commun, 12:5885-5885, 2021 Cited by PubMed Abstract: Pathogenic fungi exhibit a heavy burden on medical care and new therapies are needed. Here, we develop the fungal specific enzyme sterylglucosidase 1 (Sgl1) as a therapeutic target. Sgl1 converts the immunomodulatory glycolipid ergosterol 3β-D-glucoside to ergosterol and glucose. Previously, we found that genetic deletion of Sgl1 in the pathogenic fungus Cryptococcus neoformans (Cn) results in ergosterol 3β-D-glucoside accumulation, renders Cn non-pathogenic, and immunizes mice against secondary infections by wild-type Cn, even in condition of CD4+ T cell deficiency. Here, we disclose two distinct chemical classes that inhibit Sgl1 function in vitro and in Cn cells. Pharmacological inhibition of Sgl1 phenocopies a growth defect of the Cn Δsgl1 mutant and prevents dissemination of wild-type Cn to the brain in a mouse model of infection. Crystal structures of Sgl1 alone and with inhibitors explain Sgl1's substrate specificity and enable the rational design of antifungal agents targeting Sgl1. PubMed: 34620873DOI: 10.1038/s41467-021-26163-5 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.32 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






